氨甲环酸在重建显微外科应用的11年荟萃分析
该研究系统检索2013至2023年文献并纳入5项研究,其中4项静脉用氨甲环酸(TXA)研究进入荟萃分析,共718例患者、854个皮瓣。静脉TXA未增加皮瓣丢失、吻合口血栓/静脉淤血、血肿或系统性静脉血栓栓塞风险;局部TXA显著降低供区并发症并缩短引流时间近7.5天。
要点
- 静脉TXA不增加皮瓣丢失及血栓栓塞风险,可安全用于显微外科。
- 局部TXA使供区并发症风险降低(RR 0.52),术后引流缩短近7.5天。
- TXA可能具有抗炎促愈合作用,但仍需随机对照试验制定标准方案。
核心结论
- TXA与供区并发症减少相关,且不增加皮瓣并发症或系统性血栓栓塞事件风险。
- TXA可能具有抗炎特性促进愈合,是重建显微外科安全有效的辅助手段。
研究设计与样本
- 遵循PRISMA指南的系统综述与荟萃分析,检索PubMed、Cochrane、Embase和Google Scholar 2013至2023年临床研究。
- 两名独立评审者使用ROBINS-I工具评估偏倚风险,采用Cochrane Review Manager计算加权相对风险(wRR)和异质性(I2)。
- 共5项研究探讨显微外科TXA,其中4项静脉TXA研究纳入荟萃分析,共718例患者、854个皮瓣,403个皮瓣接受TXA。
- 静脉TXA用于308例患者,局部TXA用于36例。
主要发现
- 静脉TXA队列中,皮瓣丢失风险无差异(wRR 0.63;95% CI 0.17-2.32;p=0.49;I2=9%)。
- 吻合口血栓/静脉淤血风险无差异(wRR 0.39;p=0.06;I2=0%)。
- 血肿风险无差异(wRR 0.76;95% CI 0.21-2.75;p=0.68;I2=54%)。
- 总体系统性静脉血栓栓塞风险无差异(wRR 0.17;p=0.10;I2=0%)。
- 供区创面局部应用TXA显著降低多种并发症风险(RR 0.52;95% CI 0.29-0.94;p=0.03),术后引流时间显著缩短近7.5天(p=0.022)。
关键数值与推荐
- 静脉TXA不增加皮瓣丢失、吻合口血栓/静脉淤血、血肿或系统性静脉血栓栓塞风险。
- 局部TXA至供区创面可降低并发症风险(RR 0.52;95% CI 0.29-0.94;p=0.03)并缩短引流时间近7.5天(p=0.022)。
临床怎么用
- 重建显微外科中可考虑静脉应用TXA以减少供区并发症,无需过度担忧皮瓣血管并发症。
- 供区创面局部应用TXA可能减少并发症并缩短术后引流时间。
- 目前证据支持TXA作为安全有效的辅助手段,但标准化方案仍需随机对照试验确定。
局限性
- 纳入研究数量少(共5项,仅4项进入荟萃分析),证据级别受限于非随机研究设计。
- 局部TXA相关结论仅基于36例患者,样本量小。
- 部分结局指标异质性较高(如血肿I2=54%)。
- 缺乏随机对照试验,无法确定标准化治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of tranexamic acid (TXA) in plastic surgery is increasing due to its anti-inflammatory properties, particularly in reducing postoperative seromas. However, its role in reconstructive microsurgery remains limited due to concerns about microvascular thrombosis and flap compromise. This study reviewed the literature on TXA use in microsurgery with a meta-analysis of clinical outcomes. METHODS: A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines searched PubMed, Cochrane, Embase, and Google Scholar for clinical studies published from 2013 to 2023 utilizing TXA in microsurgical procedures. Two independent reviewers assessed the studies using the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool. Outcomes of interest included the TXA administration protocol and postoperative complications. Meta-analysis was conducted using Cochrane Review Manager, evaluating for weighted relative risk (wRR) and heterogeneity (I2) of pooled data. RESULTS: Five studies investigated TXA in microsurgery, with four using intravenous (IV) TXA and included in the meta-analysis. A total of 718 patients and 854 flaps were analyzed, with 403 flaps receiving TXA. IV TXA was used in 308 patients, and topical TXA in 36. In the IV TXA cohort, there were no differences in the incidence of complications or in the risk of flap loss (wRR, 0.63; 95% CI, 0.17-2.32; p=0.49; I2=9%), thrombosis/venous congestion of the anastomosis (wRR, 0.39; p=0.06; I2=0%), hematoma (wRR, 0.76; 95% CI, 0.21-2.75; p=0.68; I2=54%), or overall systemic venous thromboembolism (wRR, 0.17; p=0.10; I2=0%). Topical TXA to the donor site wound bed demonstrated a significant decrease in the risk of various complications (relative risk [RR], 0.52; 95% CI, 0.29-0.94; p=0.03) and a significant decrease in the duration of postoperative drains by nearly 7.5 days (p=0.022). CONCLUSION: TXA is associated with decreased donor site complications without increasing the risk of flap complications or systemic thromboembolic events in microsurgery. Additionally, TXA may demonstrate anti-inflammatory properties that promote healing. TXA is a safe and effective adjunct in reconstructive microsurgery, and a randomized controlled trial may help devise a standardized treatment protocol.
引用
- Bright AJ, Akhter MF, Gunturi AS, et al. Assessing current applications of tranexamic acid in reconstructive microsurgery and future direction: An 11-year meta-analysis. J Plast Reconstr Aesthet Surg. 2026. PMID: 41833209. doi:10.1016/j.bjps.2026.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。